Update: MDMA-Assisted Therapy for Treatment of PTSD

MAPS PBC announces positive topline results from long-term observational follow-up study on MDMA-assisted therapy for treatment of PTSD.

Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session.

Findings are consistent with previously published Phase 2 data[1] on the sustained effect of MDMA-assisted therapy for the treatment of PTSD.

Read more

A Non-Hallucinogenic LSD Analog?

BetterLife Pharma Inc., an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that findings from a study on its lead candidate BETR-001 (2-bromo-LSD) titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders” has been published in the peer-reviewed journal of Cell Report.

What do you think?

Read more